留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

EB病毒相关性移植后淋巴组织增生性疾病生物标志物的相关进展

艾亮 张盛 王强 李夏 成柯

艾亮, 张盛, 王强, 等. EB病毒相关性移植后淋巴组织增生性疾病生物标志物的相关进展[J]. 器官移植, 2021, 12(6): 767-772. doi: 10.3969/j.issn.1674-7445.2021.06.019
引用本文: 艾亮, 张盛, 王强, 等. EB病毒相关性移植后淋巴组织增生性疾病生物标志物的相关进展[J]. 器官移植, 2021, 12(6): 767-772. doi: 10.3969/j.issn.1674-7445.2021.06.019
Ai Liang, Zhang Sheng, Wang Qiang, et al. Progress on biomarkers of EB virus-related posttransplant lymphoproliferative disease[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 767-772. doi: 10.3969/j.issn.1674-7445.2021.06.019
Citation: Ai Liang, Zhang Sheng, Wang Qiang, et al. Progress on biomarkers of EB virus-related posttransplant lymphoproliferative disease[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 767-772. doi: 10.3969/j.issn.1674-7445.2021.06.019

EB病毒相关性移植后淋巴组织增生性疾病生物标志物的相关进展

doi: 10.3969/j.issn.1674-7445.2021.06.019
基金项目: 

湖南省自然科学基金 2018JJ2619

详细信息
    作者简介:

    艾亮,男,1994年生,硕士,住院医师,研究方向为肾移植,Email:al16686410167@163.com

    通讯作者:

    成柯,男,1972年生,博士,主任医师,研究方向为肾移植及肝移植,Email:Chke1972@163.com

  • 中图分类号: R617, R373

Progress on biomarkers of EB virus-related posttransplant lymphoproliferative disease

More Information
  • 摘要: 移植后淋巴组织增生性疾病(PTLD)是一系列异质性淋巴增生性疾病,也是儿童实体器官移植术后的严重并发症。超过70%的PTLD与爱泼斯坦-巴尔病毒(EBV)有关,EBV相关性B细胞淋巴瘤也是儿童器官移植术后的主要恶性肿瘤。EBV相关性PTLD在儿童实体器官移植中仍然是一个棘手的问题,主要由移植术后的免疫抑制导致机体免疫功能受损所致,但具体发生机制仍不清楚。近年来,在EBV相关性PTLD的临床诊断和治疗中,开发生物标志物以实现指导诊断和个性化治疗具有极好的应用前景。本文旨在综述实体器官移植EBV相关性PTLD的发生情况及其生物标志物的研究进展,以期为临床诊疗开拓思路。

     

  • [1] HWANG CS, MACCONMARA M, DESAI DM. Pediatric abdominal organ transplantation[J]. Surg Clin North Am, 2019, 99(1): 73-85. DOI: 10.1016/j.suc.2018.09.006.
    [2] DESTEFANO CB, MALKOVSKA V, RAFEI H, et al. DA-EPOCH-R for post-transplant lymphoproliferative disorders[J]. Eur J Haematol, 2017, 99(3): 283-285. DOI: 10.1111/ejh.12904.
    [3] FRANCIS A, JOHNSON DW, TEIXEIRA-PINTO A, et al. Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study[J]. Nephrol Dial Transplant, 2018, 33(5): 881-889. DOI: 10.1093/ndt/gfx356.
    [4] MARTINEZ OM, KRAMS SM, LAPASARAN MG, et al. Prospective analysis of EBV+ PTLD in a multi-center study of pediatric transplant recipients[J]. Transplantation, 2018, 102(Suppl 7): S319.
    [5] TERAO T, TSUSHIMA T, FUKUMOTO A, et al. EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide[J]. Int J Hematol, 2021, 114(1): 136-140. DOI: 10.1007/s12185-021-03111-z.
    [6] 明英姿, 彭博, 成柯, 等. 实体器官移植后淋巴组织增生性疾病的研究进展[J]. 器官移植, 2017, 8(2): 89-98. DOI: 10.3969/j.issn.1674-7445.2017.02.002.

    MING YZ, PENG B, CHENG K, et al. Research progress of lymphoproliferative diseases after solid organ transplantation[J]. Organ Transplant, 2017, 8(2): 89-98. DOI: 10.3969/j.issn.1674-7445.2017.02.002.
    [7] HOFLAND T, DE WEERDT I, ENDSTRA S, et al. Functional differences between EBV- and CMV-specific CD8+ T cells demonstrate heterogeneity of T cell dysfunction in CLL[J]. Hemasphere, 2020, 4(2): e337. DOI: 10.1097/HS9.0000000000000337.
    [8] GAO H, LIU R, WU N, et al. Valproic acid enhances pamidronate-sensitized cytotoxicity of Vδ2+ T cells against EBV-related lymphoproliferative cells[J]. Int Immunopharmacol, 2020, 88: 106890. DOI: 10.1016/j.intimp.2020.106890.
    [9] FRASER AR, COOPER R, SMITH LM, et al. Multi-parameter flow cytometric analysis of therapeutic EBV-specific T cells: visual assessment of product development and differentiation using dimensionality reduction with t-SNE[J]. Cytotherapy, 2019, 21(5): S21.
    [10] ABUSALAH MAH, GAN SH, AL-HATAMLEH MAI, et al. Recent advances in diagnostic approaches for Epstein-Barr virus[J]. Pathogens, 2020, 9(3): 226. DOI: 10.3390/pathogens9030226.
    [11] LAZZAROTTO T, CHIEREGHIN A, PIRALLA A, et al. Kinetics of cytomegalovirus and Epstein-Barr virus DNA in whole blood and plasma of kidney transplant recipients: implications on management strategies[J]. PLoS One, 2020, 15(8): e0238062. DOI: 10.1371/journal.pone.0238062.
    [12] SEO E, KIM J, OH SH, et al. Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients[J]. Pediatr Transplant, 2020, 24(4): e13666. DOI: 10.1111/petr.13666.
    [13] COLOMBINI E, GUZZO I, MOROLLI F, et al. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients[J]. Pediatr Nephrol, 2017, 32(8): 1433-1442. DOI: 10.1007/s00467-017-3627-2.
    [14] GREEN M, CHOQUET S. Prevention of Epstein-Barr virus infection and PTLD following SOT[M]//DHARNIDHARKA VR, GREEN M, WEBBER SA, et al. Post-transplant lymphoproliferative disorders. Cham: Springer, 2021: 191-206.
    [15] MARTINEZ OM. Biomarkers for PTLD diagnosis and therapies[J]. Pediatr Nephrol, 2020, 35(7): 1173-1181. DOI: 10.1007/s00467-019-04284-w.
    [16] MA SD, XU X, PLOWSHAY J, et al. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis[J]. J Clin Invest, 2015, 125(1): 304-315. DOI: 10.1172/JCI76357.
    [17] HATTON O, SMITH MM, ALEXANDER M, et al. Epstein-Barr virus latent membrane protein 1 regulates host B cell microRNA-155 and its target FoxO3a via PI3K p110α activation[J]. Front Microbiol, 2019, 10: 2692. DOI: 10.3389/fmicb.2019.02692.
    [18] HASSAN J, DEAN J, DE GASCUN CF, et al. Plasma EBV microRNAs in paediatric renal transplant recipients[J]. J Nephrol, 2018, 31(3): 445-451. DOI: 10.1007/s40620-017-0462-2.
    [19] NAVARI M, FULIGNI F, LAGINESTRA MA, et al. Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus[J]. Front Microbiol, 2014, 5: 728. DOI: 10.3389/fmicb.2014.00728.
    [20] ZIMMERMANN H, OSCHLIES I, FINK S, et al. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry[J]. Transplantation, 2012, 93(5): 543-550. DOI: 10.1097/TP.0b013e318242162d.
    [21] SANG AX, HARRIS-ARNOLD A, KAMBHAM N, et al. Epstein-Barr virus-associated lymphoepithelial carcinoma after pediatric liver transplant[J]. Liver Transpl, 2016, 22(6): 849-853. DOI: 10.1002/lt.24457.
    [22] DE VLAMINCK I, KHUSH KK, STREHL C, et al. Temporal response of the human virome to immunosuppression and antiviral therapy[J]. Cell, 2013, 155(5): 1178-1187. DOI: 10.1016/j.cell.2013.10.034.
    [23] DHARNIDHARKA VR, RUZINOVA MB, CHEN CC, et al. Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders[J]. Cancer Med, 2019, 8(3): 1013-1023. DOI: 10.1002/cam4.1985.
    [24] GE Y, ZHOU Z, WANG X, et al. In vitro evaluation of the therapeutic effectiveness of EBV-LMP2 recombinant adenovirus vaccine in nasopharyngeal carcinoma[J]. Biomed Pharmacother, 2020, 121: 109626. DOI: 10.1016/j.biopha.2019.109626.
    [25] TAN GW, SIVANESAN VM, ABDUL RAHMAN FI, et al. A novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma[J]. Int J Cancer, 2019, 145(8): 2260-2266. DOI: 10.1002/ijc.32173.
    [26] EVENS AM, CHOQUET S, KROLL-DESROSIERS AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era[J]. Am J Transplant, 2013, 13(6): 1512-1522. DOI: 10.1111/ajt.12211.
    [27] HABIB M, BUISSON M, LUPO J, et al. Lytic EBV infection investigated by detection of soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD[J]. Sci Rep, 2017, 7(1): 10479. DOI: 10.1038/s41598-017-09798-7.
    [28] WANG J, LIU W, ZHANG X, et al. LMP2A induces DNA methylation and expression repression of AQP3 in EBV-associated gastric carcinoma[J]. Virology, 2019, 534: 87-95. DOI: 10.1016/j.virol.2019.06.006.
    [29] HOPWOOD PA, BROOKS L, PARRATT R, et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients[J]. Transplantation, 2002, 74(2): 194-202. DOI: 10.1097/00007890-200207270-00009.
    [30] HUANG YC, LIN SJ, LIN KM, et al. Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival[J]. Blood, 2016, 128(12): 1578-1589. DOI: 10.1182/blood-2016-02-702530.
    [31] SAWADA A, INOUE M. Hematopoietic stem cell transplantation for the treatment of Epstein-Barr virus-associated T- or NK-cell lymphoproliferative diseases and associated disorders[J]. Front Pediatr, 2018, 6: 334. DOI: 10.3389/fped.2018.00334.
    [32] TOYODA M, SHIN BH, GE S, et al. Impact of desensitization on antiviral immunity in HLA-sensitized kidney transplant recipients[J]. J Immunol Res, 2017: 5672523. DOI: 10.1155/2017/5672523.
    [33] LEE KT, TAN JK, LAM AK, et al. MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: a critical review[J]. Crit Rev Oncol Hematol, 2016, 103: 1-9. DOI: 10.1016/j.critrevonc.2016.04.006.
    [34] MCAULAY KA, HAQUE T, CRAWFORD DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease[J]. Br J Cancer, 2009, 101(6): 1019-1027. DOI: 10.1038/sj.bjc.6605278.
    [35] GRINDE B. Viruses belonging to anelloviridae or circoviridae as a possible cause of chronic fatigue[J]. J Transl Med, 2020, 18(1): 485. DOI: 10.1186/s12967-020-02666-5.
    [36] CAILLARD S, LELONG C, PESSIONE F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry[J]. Am J Transplant, 2006, 6(11): 2735-2342. DOI: 10.1111/j.1600-6143.2006.01540.x.
    [37] AL HAMED R, BAZARBACHI AH, MOHTY M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities[J]. Bone Marrow Transplant, 2020, 55(1): 25-39. DOI: 10.1038/s41409-019-0548-7.
  • 加载中
图(1)
计量
  • 文章访问数:  39
  • HTML全文浏览量:  14
  • PDF下载量:  17
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-08-22
  • 刊出日期:  2021-11-15

目录

    /

    返回文章
    返回